Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

NCT01632358 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

279

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidaemia

Interventions

DRUG: TAP311 capsules
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals